Menu
Not yet recruiting NCT07284524

Intelligent Precision Knee Preservation System for Knee Osteoarthritis

No phase Interventional Knee Osteoarthritis (Knee OA)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: HTO procedure.
Who it may be relevant to
Registry conditions: Knee Osteoarthritis (Knee OA). Basic parameters: 40 years — 70 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

The Dynamic Dual-Mode Alignment Optimization and Intelligent Precision Knee Preservation System for Knee Osteoarthritis

Overview

The goal of this clinical trial is to verify whether the "dynamic dual-mode alignment optimization + intelligent precision knee-preserving system" (integrating static/kinematic target alignment, CT-based preoperative three-dimensional \[3D\] planning, 3D-printed guide plates, and intraoperative augmented reality \[AR\] real-time feedback) achieves a greater relative reduction in peak knee adduction moment (KAM) at 12 months postoperatively, while maintaining or improving knee clinical function and without increasing perioperative or long-term complication rates, compared with traditional knee-preserving strategies. The target population is patients aged 40-70 years with knee osteoarthritis (KOA; Kellgren-Lawrence grade II-III) who require high tibial osteotomy (HTO) for unilateral medial-compartment disease with mild-to-moderate varus deformity and who meet the inclusion and exclusion criteria. The main questions are: * Can the dynamic dual-mode alignment + intelligent precision system achieve a greater relative reduction in peak KAM at 12 months postoperatively than traditional knee-preserving strategies? * Can this system improve static alignment accuracy, dynamic load parameters (e.g., KAM impulse and varus thrust), and patient-reported outcome (PRO) scores without increasing complication rates? * Can 3D-printed patient-specific instrumentation (PSI) guide plates and real-time AR feedback reduce intraoperative radiation exposure and shorten operative time compared with traditional methods? Researchers will compare: Kinematic alignment (KA), traditional mechanical alignment (MA), and dynamic dual-mode alignment (DA) to evaluate the relative performance of alignment strategies; 3D-printed PSI-guided HTO versus traditional fluoroscopy-guided HTO to assess the efficacy of PSI; and AR-assisted intraoperative adjustment versus traditional fluoroscopy-based adjustment to evaluate the precision of AR navigation. Participants will: * Complete preoperative assessments, including laboratory tests (complete blood count, biochemistry, coagulation), imaging (full-length, weight-bearing lower-limb radiographs; knee CT and/or MRI as indicated), 3D gait analysis (to measure KAM, KAM impulse, and varus thrust), and PRO assessments (KOOS, WOMAC, and Lysholm scores) * Receive assigned surgical interventions: the DA group will undergo HTO guided by dual-mode alignment plus 3D-printed PSI and intraoperative AR feedback; the MA and KA groups will undergo HTO based on traditional or kinematic alignment, respectively; the traditional HTO group will undergo surgery relying on intraoperative fluoroscopy and surgeon experience. * Attend follow-up visits at 6 weeks, 3 months, 6 months, and 12 months postoperatively, including imaging to assess alignment accuracy and bone healing, gait analysis, PRO assessments, and complication monitoring. * Record medication use and rehabilitation compliance throughout the study period.

Interventions

  • Behavioral HTO procedure
    HTO procedure for knee osteoarthritis

Primary outcome measures

  • Relative ΔKAM (%) [Time frame: Preoperative, and 6 weeks, 3 months, 6 months, 12 months postoperatively]
  • HKA Accuracy [Time frame: Preoperative, and 12 months postoperatively]
  • KOOS score [Time frame: Preoperative, and 6 weeks, 3 months, 6 months, 12 months postoperatively]
  • WOMAC Osteoarthritis Index [Time frame: Preoperative, and 6 weeks, 3 months, 6 months, 12 months postoperatively]
  • HSS score [Time frame: Preoperative, and 6 weeks, 3 months, 6 months, 12 months postoperatively]
  • Lysholm score [Time frame: Preoperative, and 6 weeks, 3 months, 6 months, 12 months postoperatively]
Secondary outcome measures (4)
  • MCID achievement rate [Time frame: Preoperative, and 6 weeks, 3 months, 6 months, 12 months postoperatively]
  • Operative time [Time frame: Intraoperative]
  • Number of fluoroscopic shots [Time frame: Intraoperative]
  • Reoperation rate [Time frame: 12 months postoperatively]

Eligibility criteria

Inclusion criteria

  • Age between 40 and 70 years;
  • Unilateral medial compartment knee osteoarthritis (mild to moderate pain);
  • Mild to moderate varus deformity (5°-15°);
  • Coronal MRI showing medial meniscus extrusion (MME) >3 mm and flexion contracture <10°;
  • Intact lateral meniscus and articular cartilage;

Exclusion criteria

  • Patients with concomitant inflammatory arthritis (e.g., rheumatoid arthritis) or systemic inflammatory diseases;
  • Patients with severe varus deformity (>10°) or flexion contracture >10°;
  • Patients with lateral meniscus pathology (tear, discoid meniscus) or knee joint instability;
  • Patients with a history of major knee trauma, infection, or prior knee surgery;
  • Patients with severe patellofemoral osteoarthritis;
  • Patients with advanced medial compartment osteoarthritis (bone-on-bone contact or knee subluxation);
  • Patients who refuse second-look arthroscopy or participation in the study;
  • Patients unable to complete at least 12 months of follow-up;
  • Patients with severe osteoporosis;
  • Patients with cognitive impairment.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

China · 1 center
  • The First Affiliated Hospital of Wenzhou Medical University — Wenzhou

Identifiers

NCT: NCT07284524 · KY2025-307

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗